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Summary
Background Interest in the use of cannabis and cannabinoids to treat chronic non-cancer pain is increasing, because 
of their potential to reduce opioid dose requirements. We aimed to investigate cannabis use in people living with 
chronic non-cancer pain who had been prescribed opioids, including their reasons for use and perceived 
effectiveness of cannabis; associations between amount of cannabis use and pain, mental health, and opioid use; 
the effect of cannabis use on pain severity and interference over time; and potential opioid-sparing effects of 
cannabis.
Methods The Pain and Opioids IN Treatment study is a prospective, national, observational cohort of people with 
chronic non-cancer pain prescribed opioids. Participants were recruited through community pharmacies across 
Australia, completed baseline interviews, and were followed up with phone interviews or self-complete 
questionnaires yearly for 4 years. Recruitment took place from August 13, 2012, to April 8, 2014. Participants were 
asked about lifetime and past year chronic pain conditions, duration of chronic non-cancer pain, pain self-efficacy, 
whether pain was neuropathic, lifetime and past 12-month cannabis use, number of days cannabis was used in the 
past month, and current depression and generalised anxiety disorder. We also estimated daily oral morphine 
equivalent doses of opioids. We used logistic regression to investigate cross-sectional associations with frequency of 
cannabis use, and lagged mixed-effects models to examine temporal associations between cannabis use and 
outcomes.
Findings 1514 participants completed the baseline interview and were included in the study from 
Aug 20, 2012, to April 14, 2014. Cannabis use was common, and by 4-year follow-up, 295 (24%) participants had 
used cannabis for pain. Interest in using cannabis for pain increased from 364 (33%) participants (at baseline) to 
723 (60%) participants (at 4 years). At 4-year follow-up, compared with people with no cannabis use, we found that 
participants who used cannabis had a greater pain severity score (risk ratio 1·14, 95% CI 1·01–1·29, for less 
frequent cannabis use; and 1·17, 1·03–1·32, for daily or near-daily cannabis use), greater pain interference score 
(1·21, 1·09–1·35; and 1·14, 1·03–1·26), lower pain self-efficacy scores (0·97, 0·96–1·00; and 0·98, 0·96–1·00), and 
greater generalised anxiety disorder severity scores (1·07, 1·03–1·12; and 1·10, 1·06–1·15). We found no evidence 
of a temporal relationship between cannabis use and pain severity or pain interference, and no evidence that 
cannabis use reduced prescribed opioid use or increased rates of opioid discontinuation.
Interpretation Cannabis use was common in people with chronic non-cancer pain who had been prescribed opioids, 
but we found no evidence that cannabis use improved patient outcomes. People who used cannabis had greater pain 
and lower self-efficacy in managing pain, and there was no evidence that cannabis use reduced pain severity or 
interference or exerted an opioid-sparing effect. As cannabis use for medicinal purposes increases globally, it is 
important that large well designed clinical trials, which include people with complex comorbidities, are conducted to 
determine the efficacy of cannabis for chronic non-cancer pain.
Funding National Health and Medical Research Council and the Australian Government.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction
The use of prescribed opioids in the treatment of chronic 
non-cancer pain is controversial because of insufficient 
evidence for their long-term effectiveness1,2 and increased 
harms as opioid prescribing for chronic non-cancer pain 
has increased.3,4
Alternatives to opioids are increasingly being debated 
and considered. Reviews of cannabinoids suggest they 
might have efficacy in some chronic non-cancer pain 
conditions.5–7 In the USA,8 Canada,9 and the Netherlands,10 
chronic non-cancer pain is the most commonly cited 
reason for use of cannabis for medicinal purposes. 
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Furthermore, there is increasing discussion about the 
potential opioid-sparing effects of cannabinoids.11 Changes 
in regulations mean that there could be an increase in use 
of cannabinoid products for chronic non-cancer pain.
Longitudinal studies of cannabis use among people 
with chronic non-cancer pain are scarce. Randomised 
controlled studies typically exclude individuals with 
complex physical, substance use, and mental health 
comorbidities, who represent a substantial proportion of 
people living with chronic non-cancer pain.12 Evidence on 
efficacy in the most common causes of chronic non-
cancer pain—namely, back or neck problems, arthritis, 
and migraine, is scarce.7,13 Long-term follow-up in 
prospective studies is insufficient, with most being 12 months 
or less.14–16 Discussion about the opioid-sparing effects of 
cannabinoids has often been confined to ecological studies 
or cross-sectional surveys, which are poorly suited for 
testing causal hypotheses.
We used the Pain and Opioids IN Treatment (POINT) 
study, a national cohort of people with chronic non-
cancer pain who had been prescribed opioids, to examine 
cannabis use and pain outcomes over 4 years. We aimed 
to investigate the following: cannabis use during a 4-year 
period in people with chronic non-cancer pain who had 
been prescribed opioids, including their reasons for use 
and perceived effectiveness of cannabis; associations 
between amount of cannabis use in the past month and 
pain, mental health, and opioid use; the effect of cannabis 
use on pain severity and interference over time, 
controlling for potential confounding of demographic 
and clinical variables; and potential opioid-sparing effects 
of cannabis, controlling for potential confounding 
variables.
Methods
Study design and participants
Full details of the study design and measures included 
have been published elsewhere.12,17 POINT participants 
were recruited through community pharmacies across 
Australia (appendix). We did not have a planned period of 
recruitment, but aimed to recruit until we reached 
1500 participants. Recruitment took place from August 13, 
2012, to April 8, 2014. Participants were aged 18 years or 
older, living with chronic non-cancer pain (defined in this 
Research in context
Evidence before this study
The potential use of cannabinoids in chronic non-cancer pain 
has raised substantial interest. We did a literature review by 
searching MEDLINE, Embase, PsycINFO, CENTRAL, and 
ClinicalTrials.gov in July, 2017, with no language restrictions, for 
randomised controlled trials (RCTs) and observational studies 
relating to all cannabinoid types and specific chronic 
non-cancer pain conditions and pain-related outcomes. We 
used the following search terms: “Cannabinoids”, “Cannabis”, 
“cannab*”, “marijuana”, “marinol”, “dronabinol”, “nabilone”, 
“levonantradol”, “tetrahydrocannabinol”, “cesamet”, “delta-9-
THC”, “delta-9-tetrahydrocannabinol”, “nabiximols”, “sativex”, 
“cannabidiol”, “therapeutic use”, “analgesics”, “medical 
marijuana”, “medicinal cannabis”, “pain”, “chronic pain”, 
“Neuralgia”, and “neuropathic pain”. We identified 
91 publications, containing 104 studies, which included 
47 randomised control trials and 57 observational studies. We 
found the pooled change in pain intensity (standardised mean 
difference −0·14, 95% CI −0·20 to −0·08) was equivalent to 
3 mm on a 100 mm visual analogue scale greater than placebo. 
We graded the quality of evidence as moderate using an 
adapted version of the standard Grades of Recommendation, 
Assessment, Development and Evaluation tool. Existing clinical 
studies of the effects of cannabinoids on chronic non-cancer 
pain mainly consisted of RCTs done using a restricted range of 
cannabinoids in a small range of chronic non-cancer pain 
conditions and lacked clarity in reporting of pain outcomes.
Added value of this study
To our knowledge, our study is one of the longest, in-depth, 
prospective studies of a community cohort of people with 
various types of chronic non-cancer pain that examined the 
effects of cannabis use on pain and prescribed opioid use during 
4 years of follow-up. Cannabis use was common in our cohort, 
patients reported that it reduced their pain, and interest in 
using cannabis for pain doubled in the cohort during the 4-year 
follow-up. Nonetheless, patients who had used cannabis had 
greater pain severity and interference, lower pain self-efficacy, 
and greater generalised anxiety disorder severity than did 
patients who had not used cannabis. Unlike recent reviews that 
suggested a positive effect of cannabinoids on pain and a 
reduction in opioid use, we found no evidence of a temporal 
relationship between cannabis use and pain severity or pain 
interference, and no evidence that cannabis use reduced 
prescribed opioid use or increased rates of opioid 
discontinuation.
Implications of all the available evidence
Previous systematic reviews suggested there is moderate 
evidence that cannabinoids are effective for certain types of 
pain. Previous evidence has been scarce because of studies with 
short duration and exclusion of participants with complex 
clinical profiles. In our 4-year prospective cohort of people 
prescribed opioids for chronic non-cancer pain, we did not find 
evidence supporting claims that cannabis and cannabinoids 
improved outcomes in chronic non-cancer pain, nor that they 
reduced prescription opioid use. To date, evidence that 
cannabinoids are effective for chronic non-cancer pain and aid 
in reducing opioid use is lacking. Large, well designed clinical 
trials are required to evaluate in which patients cannabinoids 
might be effective in reducing pain severity, interference, and 
opioid doses.
See Online for appendix
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study as pain lasting longer than 3 months), taking 
prescribed schedule 8 opioids (including fentanyl, 
morphine, oxycodone, buprenorphine, methadone, and 
hydromorphone) for chronic non-cancer pain for longer 
than 6 weeks, competent in English, mentally and 
physically able to participate in telephone and self-
complete interviews, and did not have any serious 
cognitive impairments, as determined by the interviewer 
at the time of screening. A history of injecting drug use 
was not an exclusion criterion, but people currently 
prescribed pharmaceutical opioids for opioid substitution 
therapy for heroin dependence or cancer were not eligible 
for inclusion.
Written informed consent was obtained from 
participants. This study was approved by the Human 
Research Ethics Committee of the University of New 
South Wales (reference #HC12149 and #HC16916).
Measures
The measures, tools, and data domains were based on 
recommendations made by the Initiative on Methods, 
Measurement, and Pain Assessment in Clinical Trials.18,19 
Details of the interview procedure are provided in the 
appendix. Baseline interviews comprised a phone 
interview and self-complete survey and were done from 
Aug 20, 2012, to April 14, 2014. 3-month self-complete 
surveys were done as close to 3 months after baseline 
interview as possible and occurred from Nov 15, 2012, to 
Nov 1, 2014. The 3-month self-complete questionnaire was 
a reduced questionnaire with a smaller number of 
measures included and is therefore not included in the 
current analysis as many of the measures used, such as 
Pain Self-Efficacy Questionnaire (PSEQ) and questions 
regarding cannabis use, were not included. Furthermore, 
for consistency in analyses, we used interviews which were 
12 months apart. 12-month self-complete questionnaires 
occurred 12 months after baseline interviews, between 
Aug 28, 2013, and Dec 4, 2015. 2-year interviews were done 
from Aug 12, 2014, to March 23, 2016. The 3-year interview 
was part of a new funding grant and all participants were 
interviewed annually by calendar year. 3-year interviews 
took place between Jan 11, 2016, and Jan 3, 2017. 4-year 
follow-ups were done from Jan 9, 2017, to Dec 12, 2017.
We collected data on age, sex, relationship status, and 
current work status. Relationship status and work status 
data were collected at all timepoints. Sex and age data 
were collected only at baseline.
Participants were asked about chronic pain conditions 
in their lifetime and during the past year, and duration 
of chronic non-cancer pain. As pain is only one of several 
core outcomes to consider when evaluating interventions 
for chronic non-cancer pain,18 we used the pain severity 
and interference (how pain affects sleep, daily living, 
working ability, and social interaction) subscales of the 
Brief Pain Inventory (BPI),20 with higher scores 
indicating greater pain severity or interference (score 
range 0–10).
Pain self-efficacy relates to an individual’s beliefs about 
the extent to which they can do daily activities despite 
their pain; this was measured using the PSEQ21 (score 
out of 60, higher scores indicating greater self-efficacy). 
Participants were asked at baseline “Is your pain 
neuropathic? That is, pain that burns or tingles (either 
diagnosed by self or doctor).”
Daily oral morphine equivalent doses of opioids, in mg 
per day, were estimated using conversion units 
established through synthesis of clinical references,22 
using a medication diary. At each follow-up, we confirmed 
whether participants were still taking a schedule 8 opioid.
Participants were asked about lifetime and past 
12-month use of cannabis, and number of days used in 
the past month, in general and for pain specifically. 
Frequency of cannabis use in the past month was 
categorised as no use (0 days), less frequent use (1–19 days), 
and near-daily or daily use (≥20 days of cannabis use, 
approximately five times a week or more).
Figure: Study flow chart
Patient flow and reasons for exclusion between study referral and baseline 
interview are provided in the appendix.
1514 patients completed baseline interview 
1396 contacted for 1-year follow-up
1235 completed follow-up
124 could not be contacted
37 refused
71 withdrew at 3-month follow-up
26 withdrew at 12-month follow-up
21 died
1359 contacted for 2-year follow-up
1277 completed follow-up
79 could not be contacted
3 refused
1301 contacted for 3-year follow-up
1211 completed follow-up
79 could not be contacted
11 refused
1260 contacted for 4-year follow-up
1217 completed follow-up
29 could not be contacted
14 refused
15 withdrew
22 died
19 withdrew
39 died
16 withdrew
25 died
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Participants who reported lifetime use of cannabis for 
pain but had discontinued use were asked their reasons 
for doing so. Those who reported past 12-month cannabis 
use were asked further questions about reasons for use 
(appendix). All participants were asked “If you had access 
to cannabis, would you want to use it?” at each wave 
(excluding the 1-year follow-up). Based on a similar 
question in the BPI, we asked participants to rate the 
effectiveness of cannabis for their pain on a scale of 0 (no 
relief) to 10 (complete relief).
Current depression and generalised anxiety disorder 
were measured by the Patient Health Questionnaire 9 
(PHQ-9) and Generalized Anxiety Disorder 7-Item Scale 
(GAD-7).23,24 We defined moderate to severe depression as 
a PHQ-9 score of 10 or greater.23 We defined moderate to 
severe anxiety as a GAD-7 score of 10 or greater.24 We 
used the Composite International Diagnostic Interview 
3.0 substance use module to assess lifetime International 
Statistical Classification of Diseases and Related Health 
Problems, Tenth Revision diagnostic codes for harmful 
use and dependence.25
Statistical analysis
We aimed to recruit 2000 participants, but then limited 
this number to 1500 because of funding and time 
constraints. For descriptive statistics, means and SDs 
were computed when data were normally distributed, 
and medians and IQRs when data were skewed.26
To investigate cross-sectional associations with 
cannabis use frequency, we used multinomial logistic 
regression models for univariate comparisons of people 
at each wave who reported less frequent cannabis use 
and near-daily or daily cannabis use (compared with 
people who had not used cannabis). Variables identified 
in previous research as related to the outcomes were 
included. For interpretability, risk ratios (RRs) for oral 
morphine equivalent doses are reported per 100 units. 
Additional analyses of the demographic and clinical 
associations between prevalent and incident cannabis 
use are presented and discussed in the appendix.
For prospective associations between cannabis use and 
outcomes, we used lagged mixed-effects models to 
examine temporal associations between cannabis use (the 
exposure) and pain severity, pain interference, and oral 
morphine equivalent doses (the outcomes), incorporating 
a random intercept for individuals to account for the 
repeated measures design and examining unadjusted and 
adjusted associations. We analysed data from baseline 
interviews and the four annual follow-up waves, with 
outcomes for the following year, and constructed four 
models. In the first model, we compared the outcome of 
interest in people who used cannabis (less frequent use, 
and near-daily or daily use) versus those who had never 
used cannabis. In the second, we adjusted for the outcome 
at the previous wave. In the third, we additionally adjusted 
for clinical covariates identified in previous research as 
related to the outcomes (age, sex, duration of pain, 
generalised anxiety disorder severity, and history of 
substance use).26 Furthermore, for analysis of pain severity, 
we also adjusted for oral morphine, for pain interference, 
we adjusted for pain severity and oral morphine 
equivalent, and for oral morphine equivalent, we adjusted 
for pain severity. In the final model, we further adjusted 
for PSEQ results (we had some missing data as the PSEQ 
was not completed at the 1-year interview).
Analyses were done using Stata version 15.0. We used 
the Stata command margins (or mimrgns for multiple 
imputation) to obtain adjusted means. For details of 
sensitivity analyses see the appendix.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
Baseline 
(n=1514)
1-year 
follow-up 
(n=1235)
2-year 
follow-up 
(n=1277)
3-year 
follow-up 
(n=1211)
4-year 
follow-up 
(n=1217)
Demographics
Age, years 58 (48–67) 58 (49–68) 59 (50–69) 60 (50–69) 60 (50–70)
Sex
Male 672 (44%) 542 (44%) 555 (43%) 524 (43%) 524 (43%)
Female 842 (56%) 693 (56%) 722 (57%) 687 (57%) 693 (57%)
Pain
BPI pain severity score 5·1 (1·79) 5·3 (1·9) 5·0 (1·9) 4·9 (1·9) 4·8 (1·9)
BPI pain interference 
score
5·7 (2·3) 5·7 (2·4) 5·4 (2·4) 5·5 (2·4) 5·4 (2·4)
Prescribed opioid use
Oral morphine 
equivalent, mg/day
75 (36–150) 61 (24–135) 6 (25–135) 60 (22–126) 57 (15–125)
Discontinued opioids ·· 131 (10·6%) 174 (13·6%) 202 (16·7%) 246 (20·2%)
Cannabis use
Lifetime use 649 (43%) ·· ·· ·· ··
Past 12 months 195 (13%) 135 (11%) 170 (13%) 173 (14%) 192 (16%)
Past month use 126 (8%) 112 (9%) 123 (10%) 132 (11%) 155 (13%)
Frequency of use in the past month*
None 1319 (91%) 1085 (91%) 1151 (90%) 1078 (89%) 1047 (86%)
1–19 days (less 
frequent)
78 (5%) 65 (5%) 70 (5%) 70 (6%) 78 (6%)
20–31 days (near-
daily or daily)
48 (3%) 47 (4%) 53 (4%) 62 (5%) 79 (6%)
Ever used for pain relief 237 (16%) 220 (18%) 260 (20%) 267 (22%) 295 (24%)
Used for pain relief in 
the past 12 months
·· 123 (10%) 151 (12%) 145 (12%) 168 (14%)
Used for pain relief in 
the past month†
85 (6%) ·· 111 (9%) 121 (10%) 134 (11%)
Effectiveness of 
cannabis for pain (out 
of 10)
6·5 (2·9) 5·0 (3·5) 7·3 (2·2) 7·0 (2·2) 7·2 (2·3)
Would use it if had 
access†
364 (33%)‡ ·· 562 (44%) 649 (54%) 723 (60%)
Data are median (IQR), n (%), or mean (SD). BPI=Brief Pain Inventory. *Data were missing for some patients. †Data not 
collected at 1-year timepoint. ‡Data missing for 396 patients.
Table 1: Sociodemographic characteristics, pain, prescribed opioid use, and cannabis use among the Pain 
and Opioids IN Treatment sample, by study wave
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all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Of the 2091 people we assessed for eligibility, 1873 (90%) 
were eligible for inclusion and 1514 (81%) completed the 
baseline interview (appendix p 7). At each follow-up wave, 
at least 80% of the original participants completed the 
assessment (figure).
At baseline, 44% of the cohort were male, and the 
median age was 58 years (IQR 48–67; table 1). 737 (49%) 
participants were unemployed and 469 (31%) had retired 
No cannabis use Less frequent cannabis 
use (<20 days)
Daily or near-daily 
cannabis use 
(≥20 days)
Unadjusted
Less frequent cannabis use 
(<20 days) vs no cannabis use
Daily or near-daily cannabis use 
(≥20 days) vs no cannabis use
RR (95% CI) p value RR (95% CI) p value
Duration of pain, 
years*
10·0 (4–20) 12·5 (6–21) 13·0 (5-22) 1·00 (0·99–1·02) 0·484 1·00 (0·98–1·02) 0·901
BPI pain severity score
Baseline 5·1 (1·8) 5·3 (1·9) 5·1 (1·4) 1·09 (0·96–1·24) 0·19 1·00 (0·86–1·19) 0·906
1-year 5·3 (2·0) 5·4 (1·8) 5·6 (1·6) 1·03 (0·90–1·17) 0·703 1·09 (0·93–1·27) 0·27
2-year 5·0 (1·9) 5·4 (1·9) 5·6 (1·9) 1·12 (0·98–1·27) 0·090 1·20 (1·03–1·39) 0·020
3-year 4·8 (1·9) 5·4 (1·8) 5·5 (1·6) 1·19 (1·04–1·36) 0·011 1·21 (1·05–1·40) 0·0081
4-year 4·7 (1·9) 5·2 (1·9) 5·3 (1·8) 1·14 (1·01–1·29) 0·031 1·17 (1·03–1·32) 0·013
BPI pain interference score
Baseline 5·6 (2·3) 6·0 (2·2) 6·2 (1·5) 1·08 (0·98–1·21) 0·13 1·13 (0·99–1·30) 0·078
1-year 5·6 (2·4) 6·2 (2·2) 6·4 (2·0) 1·11 (0·99–1·24) 0·076 1·15 (1·01–1·31) 0·039
2-year 5·3 (2·4) 6·2 (2·3) 6·2 (1·8) 1·18 (1·05–1·31) 0·0035 1·18 (1·04–1·33) 0·010
3-year 5·4 (2·4) 6·5 (2·0) 6·4 (2·0) 1·23 (1·10–1·38) 0·0003 1·22 (1·08–1·38) 0·0011
4-year 5·3 (2·4) 6·3 (2·3) 6·0 (2·3) 1·21 (1·09–1·35) 0·0004 1·14 (1·03–1·26) 0·0091
PSEQ score
Baseline 29·7 (13·6) 26·4 (12·7) 25·6 (9·8) 0·98 (0·97–1·00) 0·039 0·98 (0·96–1·00) 0·048
1-year† ·· ·· ·· ·· ·· ·· ··
2-year 33·7 (13·4) 27·8 (11·2) 29·6 (11·4) 0·97 (0·95–0·99) 0·0004 0·98 (0·96–1·00) 0·029
3-year 34·4 (13·2) 28·1 (12·3) 28·6 (13·1) 0·96 (0·95–0·98) 0·0001 0·97 (0·95–0·99) 0·0008
4-year 34·2 (13·9) 30·2 (12·7) 30·6 (13·3) 0·97 (0·96–1·00) 0·015 0·98 (0·96–1·00) 0·026
Generalized Anxiety Disorder 7-item scale severity score
Baseline 5·3 (5·3) 7·2 (5·5) 8·0 (5·5) 1·06 (1·02–1·10) 0·0023 1·09 (1·04–1·14) 0·0007
1-year 5·1 (5·3) 7·4 (5·3) 8·9 (7·2) 1·07 (1·03–1·12) 0·0012 1·11 (1·06–1·16) <0·0001
2-year 4·5 (4·8) 7·5 (5·5) 6·9 (5·8) 1·11 (1·06–1·15) <0·0001 1·09 (1·03–1·14) 0·0004
3-year 4·5 (4·8) 6·7 (5·5) 8·1 (5·9) 1·08 (1·03–1·13) 0·0004 1·12 (1·07–1·17) <0·0001
4-year 4·3 (4·9) 6·4 (5·1) 7·3 (6·1) 1·07 (1·03–1·12) 0·0005 1·10 (1·06–1·15) <0·0001
Oral morphine equivalent‡
Baseline 70 (35–140) 84 (38–188) 90 (33–171) 1·21 (1·01–1·44)§ 0·040 1·05 (0·80–1·37) 0·72
1-year 60 (23–135) 88 (44–152) 90 (31–240) 1·05 (0·85–1·30) 0·64 1·39 (1·18–1·63) 0·0001
2-year 60 (24–135) 87 (52–191) 80 (30–165) 1·12 (0·98–1·27) 0·082 1·14 (0·99–1·30) 0·063
3-year 60 (22–120) 71 (39–180) 60 (23–138) 1·15 (0·89–1·29) 0·072 1·07 (0·89–1·29) 0·47
4-year 55 (15–124) 63 (23–135) 49 (8–135) 1·04 (0·88–1·22) 0·65 1·01 (0·85–1·21) 0·89
Percentage that discontinued opioids, %
1-year 10·8 (9·1–12·8) 9·2 (4·1–19·4) 10·6 (4·3–23·8) 0·59 (0·21–1·65) 0·31 0·88 (0·31–2·52) 0·81
2-year 13·8 (11·9–15·9) 7·1 (2·9–16·3) 18·9 (10·2–32·1) 0·48 (0·19–1·21) 0·12 1·44 (0·71–2·94) 0·304
3-year 16·8 (14·7–19·1) 15·7 (8·8–26·5) 16·1 (8·7–27·8) 0·92 (0·48–1·79) 0·81 0·95 (0·48–1·91) 0·89
4-year 20·9 (18·6–23·5) 9·0 (5·1–19·4) 21·5 (13·7–32·2) 0·38 (0·17–0·83) 0·016 1·05 (0·60–1·84) 0·85
Data are median (IQR) or mean (SD), unless otherwise indicated. RR=risk ratio. BPI=Brief Pain Inventory. PSEQ=pain self-efficacy questionnaire. *Only asked at baseline. †Data 
on PSEQ not collected at 1-year timepoint. ‡RR based on per 100 units.
Table 2: Bivariate cross-sectional associations between amount of cannabis use in the past month (days of use) and pain, anxiety, and medication use in 
the Pain and Opioids IN Treatment cohort, by study wave
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from work. Participants had been living with chronic 
non-cancer pain for a median of 10 years (IQR 4·5–20·0) 
and had been prescribed a strong opioid for a median of 
4 years (1·5–10·0). The median oral morphine equivalent 
taken was 75 mg/day (36–150). The most common types 
of pain reported at baseline were back or neck pain 
(1159 [77%] participants), followed by arthritis (933 [62%] 
participants), and comorbid pain was common, with 
participants reporting a median of two (IQR 2–3) chronic 
pain conditions at baseline in the preceding 12 months. 
937 (62%) participants reported neuropathic pain at 
baseline.
Using a random sample of 71 pharmacies, we compared 
the characteristics of all customers obtaining opioids 
during the 6-week recruitment window with the study 
cohort overall. Among 800 customers who recorded 
purchasing opioids in these pharmacies, 418 (52%) were 
female (vs 842 [55%] in the POINT cohort) and 58 (7%) 
were aged 18–34 years (vs 73 [5%]), 438 (55%) were aged 
35–64 years (vs 952 [62%]), and 304 (38%) were aged 
65 years or older (vs 489 [33%]). 500 (63%) people were 
prescribed oxycodone (vs 938 [62%] in the POINT cohort), 
138 (17%) were prescribed morphine (vs 225 [15%]), and 
190 (24%) were prescribed buprenorphine patches (vs 
332 [21%]).
At baseline, two-fifths of the cohort reported ever using 
cannabis, 195 (13%) reported use in the past 12 months, 
and 126 (9%) reported use in the past month. Both past 
12-month and past-month use increased from baseline to 
the 4-year timepoint (table 1).
At baseline, approximately one in six participants 
reported that they had used cannabis for pain in their 
lifetime. Past 12-month and past-month reporting of 
cannabis use for pain also increased over time. The 
proportion of participants reporting cannabis use on 
1–19 days (categorised as less frequent use) in the month 
before interview remained relatively stable. The pro-
portion reporting use on 20–31 days in the past month 
(categorised as near-daily or daily use) increased from 
3% at baseline to 7% at 4-year follow-up (table 1).
At baseline, participants who had used cannabis for 
pain rated its mean effectiveness for their pain as 6·5 out 
of 10 (with 10 being extremely effective; table 1). The 
percentage of participants reporting that they would use 
cannabis if they had access to it increased from 33% at 
baseline to 60% at 4-year follow-up.
At the 3-year and 4-year follow-up waves, participants 
who reported cannabis use in the past month were asked 
whether it influenced their use of opioid medication. 
Most participants reported that cannabis had no effect on 
their use of opioid medication (3-year follow-up 103 [78%] 
of 132 participants; 4-year follow-up 105 [70%] of 
151 participants). At 3-year follow-up, 29 (22%) of 
132 participants, and at 4-year follow-up, 46 (30%) of 
151 participants reported that they sometimes or regularly 
reduced their opioid medication when using cannabis 
(appendix). There were no differences in age, sex, pain 
severity or interference, or oral morphine equivalent 
between cannabis users who reported cannabis 
sometimes or regularly reduced their opioid use, 
compared with those who said it had no such effect (data 
not shown).
Of participants currently using cannabis, the most 
common reasons for use at both 3-year and 4-year follow-
up were to relieve pain (3-year follow-up 142 [83%] of 
174 participants; 4-year follow-up 157 [83%] of 
190 participants) and pain-related distress (3-year follow-
up 118 [68%] of 174 participants; 4-year follow-up 
140 [73%] of 192 participants), to improve sleep (3-year 
follow-up 116 [67%] of 174 participants; 4-year follow-up 
122 [64%] of 190 participants), and for general relaxation 
(3-year follow-up 126 [72%] of 175 participants; 4-year 
follow-up 124 [65%] of 192 participants; appendix). 
Participants who had previously used cannabis for pain, 
but were no longer doing so, were asked about their 
reasons for stopping. The most common reasons were 
side-effects (3-year follow-up 46 [28%] of 166 participants; 
4-year follow-up 31 [23%] of 134 participants), legal 
concerns (3-year follow-up 43 [26%] of 166 participants; 
4-year follow-up 24 [18%] of 134 participants), difficulties 
accessing cannabis (3-year follow-up 30 [18%] of 
166 participants; 4-year follow-up 27 [20%] of 
134 participants), and ineffectiveness in relieving pain 
(3-year follow-up 37 [22%] of 166 participants; 4-year 
follow-up 16 [12%] of 134 participants; appendix).
Current level of pain severity
Adjusted 
mean (SE)
β 95% CI p value
Cannabis use at previous study wave
No cannabis use (ref) 5·0 (0·05) ·· ·· ··
Less frequent use 5·1 (0·12) 0·16 −0·07 to 0·39 0·18
Near-daily or daily use 5·5 (0·13) 0·53 0·27 to 0·80 0·0001
Adjusted for pain severity at previous study wave
No cannabis use (ref) 5·0 (0·02) ·· ·· ··
Less frequent use 5·0 (0·10) 0·06 −0·12 to 0·26 0·51
Near-daily or daily use 5·2 (0·10) 0·21 0·01 to 0·40 0·037
Adjusted for previous pain severity and clinical covariates*
No cannabis use (ref) 4·9 (0·03) ·· ·· ··
Less frequent use 5·0 (0·13) 0·35 −0·01 to 0·71 0·061
Near-daily or daily use 5·1 (0·14) 0·45 −0·21 to 1·11 0·18
Adjusted for previous pain severity and clinical covariates* and Pain 
Self-Efficacy Questionnaire
No cannabis use (ref) 4·9 (0·03) ·· ·· ··
Less frequent use 5·1 (0·13) 0·37 −0·01 to 0·75 0·056
Near-daily or daily use 5·2 (0·14) 0·43 −0·23 to 1·10 0·201
*Covariates were Brief Pain Inventory severity at previous study wave, age, sex, 
duration of pain, oral morphine equivalent, generalised anxiety disorder severity, 
baseline lifetime International Statistical Classification of Diseases and Related 
Health Problems, Tenth Revision substance use disorder, and time. 
Table 3: Lagged mixed-effects linear regression examining the effect of 
cannabis use at the previous study wave on pain severity at the 
following wave (complete case analysis)
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With a few exceptions, at each follow-up, people who 
were using cannabis (less frequent or daily or near-daily 
use) reported greater pain severity and pain interference, 
lower pain self-efficacy, and higher levels of generalised 
anxiety disorder than those not using cannabis (table 2). 
The associations were consistent for less frequent and 
near-daily users (table 2). For example, at the 4-year 
interview, compared with people with no cannabis use, 
those with less frequent and daily or near-daily use had 
greater pain severity scores, greater pain interference 
scores, lower pain self-efficacy scores, and greater 
generalised anxiety disorder severity scores.
Few differences were reported in oral morphine 
equivalent consumption or the proportion of participants 
who discontinued opioids between those using cannabis 
at different frequencies. However, people who reported 
less frequent cannabis use were less likely to discontinue 
opioids at 4 years (9%) than those reporting no use (21%), 
despite no difference in oral morphine equivalent at 
4-year follow-up (table 2).
Using lagged-effects models, we examined the effect of 
past cannabis use on current pain severity (table 3), current 
pain interference (table 4), and current oral morphine 
equivalent consumption (table 5) in people using cannabis 
compared with those not using cannabis (complete case 
analysis; for multiple imputation analysis see appendix). 
In the unadjusted model, near-daily or daily cannabis 
users had significantly greater pain severity than did 
people who had not used cannabis (difference of 0·5 on a 
10-point scale; table 3). This difference, although still 
significant, was reduced by inclusion of previous pain 
severity score. In adjusted models that included clinical 
covariates and pain self-efficacy, we found no association 
between past cannabis use and current pain severity.
People who had reported use of cannabis at the 
previous wave had greater pain interference at 
subsequent follow-up than did those who had not used 
cannabis (table 4). In adjusted models, after controlling 
for age, sex, previous pain interference, pain factors 
(eg, duration of pain, pain severity, and pain self-efficacy), 
and oral morphine equivalent, previous cannabis use 
was not independently associated with current pain 
interference.
We did not detect an association between cannabis use 
in the previous wave and reduced oral morphine 
equivalent at subsequent follow-up; we found no 
association in the univariate model and no independent 
Current amount of pain interference
Adjusted 
mean (SE)
β 95% CI p value
Cannabis use in previous study wave
No cannabis use (ref) 5·4 (0·06) ·· ·· ··
Less frequent use 5·8 (0·14) 0·38 0·11 to 0·66 0·0065
Near-daily or daily use 5·9 (0·15) 0·46 0·15 to 0·77 0·0034
Adjusted for pain interference in previous study wave
No cannabis use (ref) 5·4 (0·03) ·· ·· ··
Less frequent use 5·8 (0·12) 0·32 0·08 to 0·55 0·0087
Near-daily or daily use 5·6 (0·11) 0·15 −0·08 to 0·37 0·20
Adjusted for previous oral morphine equivalent and clinical 
covariates*
No cannabis use (ref) 5·3 (0·03) ·· ·· ··
Less frequent use 5·6 (0·14) 0·33 −0·23 to 0·89 0·25
Near-daily or daily use 5·2 (0·15) −0·56 −1·41 to 0·28 0·19
Adjusted for previous oral morphine equivalent and clinical 
covariates* and Pain Self-Efficacy Questionnaire
No cannabis use (ref) 5·4 (0·04) ·· ·· ··
Less frequent use 5·7 (0·16) 0·35 −0·22 to 0·92 0·23
Near-daily or daily use 5·2 (0·19) −0·63 −1·46 to 0·19 0·13
*Covariates were Brief Pain Inventory interference at previous study wave, age, 
sex, duration of pain, Brief Pain Inventory severity score, oral morphine 
equivalent, generalised anxiety disorder severity, baseline lifetime International 
Statistical Classification of Diseases and Related Health Problems, Tenth Revision 
substance use disorder, and time.
Table 4: Lagged mixed-effects linear regression examining the effect of 
cannabis use at the previous study wave on pain interference at the 
following wave (complete case analysis)
Current oral morphine equivalent use mg/day
Adjusted 
mean (SE)
β 95% CI p value
Cannabis use in previous study wave
No cannabis use 
(ref)
97·5 (2·77) ·· ·· ··
Less frequent use 100·7 (7·46) 3·31 −11·74 to 18·36 0·67
Near-daily or daily 
use
105·3 (13·44) 7·84 −18·75 to 34·44 0·56
Adjusted for oral morphine equivalent in previous study wave
No cannabis use 
(ref)
96·3 (1·32) ·· ·· ··
Less frequent use 91·7 (5·15) −4·56 −15·13 to 6·01 0·40
Near-daily or daily 
use
100·3 (7·43) 4·08 −10·79 to 18·95 0·59
Adjusted for previous oral morphine equivalent and clinical 
covariates*
No cannabis use 
(ref)
91·2 (1·45) ·· ·· ··
Less frequent use 88·2 (6·78) 1·05 −31·25 to 33·35 0·95
Near-daily or daily 
use
91·5 (8·88) 27·64 −28·87 to 84·15 0·34
Adjusted for previous oral morphine equivalent and clinical 
covariates* and Pain Self-Efficacy Questionnaire
No cannabis use 
(ref)
85·5 (1·74) ·· ·· ··
Less frequent use 95·1 (8·85) 7·00 26·97 to 40·96 0·69
Near-daily or daily 
use
97·1 (12·66) 32·76 −25·04 to 90·57 0·27
*Covariates were oral morphine equivalent at previous study wave, age, sex, 
duration of pain, Brief Pain Inventory severity score, generalised anxiety disorder 
severity, baseline lifetime International Statistical Classification of Diseases and 
Related Health Problems, Tenth Revision substance use disorder, and time.
Table 5: Lagged mixed-effects linear regression examining the effect of 
cannabis use at the previous study wave on amount of opioid use at the 
following wave (complete case analysis)
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association after controlling for other variables (table 5; 
for analysis based on multiple imputation see appendix).
We did sensitivity tests to examine the robustness 
of the findings. Sensitivity analyses using log trans-
formations of oral morphine equivalent in categories 
(0 mg, 1–20 mg, 21–90 mg, 91–199 mg, and ≥200 mg) 
found similar results to those presented here (appendix). 
We ran post-hoc mixed-effects models among 
participants who self-reported neuropathic pain and 
adjusted for neuropathic pain and found no significant 
effect of past cannabis use on pain severity, interference, 
or oral morphine equivalent (appendix).
Discussion
To our knowledge, this is one of the longest, in-depth, 
prospective studies of a community cohort of people with 
chronic non-cancer pain, examining the effects of 
cannabis use on pain and prescribed opioid use. Cannabis 
use was common in our cohort, patients reported that it 
reduced their pain, and the proportion interested in using 
cannabis for pain doubled over the 4-year follow-up. We 
found that patients who had used cannabis had greater 
pain severity and interference, lower pain self-efficacy, 
and greater generalised anxiety severity than did patients 
who had not used cannabis.
We found no evidence of a temporal relationship 
between cannabis use and pain severity or pain 
interference, and no evidence that cannabis use reduced 
prescribed opioid use or increased opioid discontinuation. 
The most common reasons for discontinuing cannabis 
use included side-effects, lack of efficacy, access 
difficulties, and legal concerns. Nonetheless, our data 
and other population surveys27 highlight growing 
community interest in using cannabis for pain.
A legislative change on Oct 30, 2016, decriminalised 
medicinal use and supply of cannabis and cannabinoids;13 
perceptions of efficacy and safety of cannabis for medical 
use might therefore increase in Australia, as they have 
done in other jurisdictions.28 Few data in our 4-year 
follow-up were collected after this change, and very few 
individuals nationally have accessed cannabinoids for 
medicinal purposes, so our cohort primarily used illicitly 
produced cannabis. Increased availability of medicinal 
cannabinoids might increase use among people living 
with chronic non-cancer pain in Australia, although 
access is still restricted and licensed cannabinoid 
medications are expensive. Additionally, in our study it is 
unlikely cannabis was consumed under the guidance of a 
medical practitioner. Expectations that cannabis will 
reduce pain and opioid use might differ for participants 
using medicinal cannabis compared with those using 
illicit cannabis. High-quality, double-blind, randomised, 
placebo-controlled trials examining expectancy effects, 
which are lacking for most chronic non-cancer conditions, 
might shed further light.
We found inconsistencies in our findings between 
what participants reported and our statistical assessment 
of associations. Although participants who used cannabis 
reported that the mean effectiveness of cannabis on pain 
was 7 out of a possible score of 10, in unadjusted cross-
sectional and longitudinal analyses, people who used 
cannabis in the past month reported greater pain severity 
and interference than those who had not used cannabis 
in the past month. In adjusted longitudinal analyses, we 
found no association between cannabis and pain severity 
or interference. This finding is inconsistent with previous 
studies that have found cannabis reduced pain severity.14–16
In our cohort, patients with chronic non-cancer pain 
who used cannabis reported significantly greater pain 
severity than those not using cannabis, consistent with 
surveys of medicinal users who report using cannabis 
because of a failure of conventional treatments.29,30 Those 
using cannabis with the intent of relieving their pain 
might represent a patient population with more distress 
and poorer coping mechanisms, as evidenced in our 
study by the lower pain self-efficacy scores for people 
who used cannabis. It could be that in the absence of 
cannabis use, pain severity and interference might have 
been worse. However, our study supports recent research 
that suggests cannabis use is associated with reduced 
self-efficacy in managing depression and anxiety.31 
Although previous reviews have found moderate support 
for cannabis use in reducing chronic non-cancer pain,5–7,8 
they have mainly relied on randomised controlled trials, 
in which people with complex comorbidities have been 
excluded. Considering recent findings31 and our study, it 
is important that future research focuses on self-efficacy 
and complexity of patients to better understand what 
types of patients with chronic non-cancer pain might 
benefit from using cannabinoids.
Previous cross-sectional studies have suggested 
cannabis might have opioid-sparing effects in people 
with chronic non-cancer pain,32,33 although a systematic 
review found a lack of high-quality clinical studies testing 
potential opioid-sparing effects.11 In our study, using both 
cross-sectional and longitudinal analytic approaches, we 
found no evidence that cannabis use was associated with 
reduced opioid use or opioid cessation. This finding 
needs to be qualified as participants had access only to 
illicit cannabis and were not taking cannabis as part of 
structured pain management under medical supervision.
To our knowledge, our study was unique in exploring 
temporal associations between cannabis use, pain, and 
opioid use in a large cohort with multiple assessment 
waves and low attrition. There might be concern that we 
did not recruit a representative sample of people 
prescribed opioids for chronic non-cancer pain. To 
appraise the generalisability of the study cohort, we 
collected data from a random sample of 71 pharmacies 
on the characteristics of all customers obtaining opioids 
during their 6-week recruitment window. These data 
showed important similarities between the cohort we 
recruited and customers overall in sex, age, and type of 
opioid prescribed.
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Although our data were self-reported, this method of 
collection is reasonably reliable,34 particularly when there 
are no disincentives for being honest.35 All participants 
were assured of confidentiality and that the data would 
be de-identified; however, we did no independent checks 
of participant reports of cannabis use. Because of the 
illegality of cannabis during the study period, it is 
possible that cannabis use has been under-reported. 
However, other epidemiological studies that have 
reported cannabis use associated with reduced opioid 
consumption have also depended on self-reported 
cannabis and opioid use.32,33,36,37 Additionally, we recorded 
frequency of cannabis use, rather than quantity and type 
of cannabis, but there are major complexities in reliably 
measuring total cannabis consumption given variations 
in tetrahydrocannabinol content and amounts consumed 
in a session of use.38,39 Finally, although we found no 
significant association between cannabis use and pain, it 
is difficult to completely understand the effects of 
cannabis on pain in an observational study.
In conclusion, cannabis use is common in people with 
chronic non-cancer pain who have been prescribed 
opioids, and interest in medicinal use of cannabis is 
increasing. We found no evidence that cannabis use 
improved patient outcomes; those who used cannabis 
had greater pain and lower self-efficacy in managing 
pain. Furthermore, we found no evidence that cannabis 
use reduced pain interference or exerted an opioid-
sparing effect.
Contributors
GCa conceived the paper with LD, NL, WDH, and RB. GCa and GCh 
analysed the data. GCh, TD, and RB provided oversight for all statistical 
analyses. All authors made substantial contributions to critical review, 
editing, and revision of the manuscript, and all authors approved the 
final version.
Declaration of interests
GCa reports grants from Reckitt Benckiser outside the submitted work. 
WDH reports grants from Australian Therapeutic Goods Administration 
and personal fees as a Member of the Australian Advisory Council on 
Medical Uses of Cannabis, both outside the submitted work. AP reports 
grants from Mundipharma and an untied educational grant from 
Sequirus for studies of tapentadol, both outside the submitted work. NL 
has received research grant funding from Indivior, Braeburn, and NSW 
Health, and consultancies or advisory board participation from Indivior 
and Mundipharma, all outside the submitted work. RB reports grants 
from Indivior for the development of an opioid-related behaviour scale 
and a study of opioid substitution therapy uptake among patients with 
chronic non-cancer pain, all outside the submitted work. BL reports 
grants from Reckitt Benckiser for studies of the development of an 
opioid-related behaviour scale, and a study of opioid substitution therapy 
uptake among patients with chronic non-cancer pain; and Indivior for 
studies of buprenorphine-naloxone and buprenorphine depot; an untied 
educational grant from Seqirus for studies of tapentadol; and grants 
from Mundipharma, all outside the submitted work. SN reports grants 
from the National Drug and Alcohol Research Centre during the conduct 
of the study, and grants from Indivior outside the submitted work. MC 
reports personal fees from Mundipharma outside the submitted work. 
RPM reports National Health and Medical Research Council project 
grants during the conduct of the study. MF received investigator-initiated 
untied educational grants from Indivior for studies of buprenorphine 
depot and naloxone; and an untied educational grant from Seqirus for 
studies of tapentadol, all outside the submitted work. LD received grants 
from Indivior for studies of buprenorphine-naloxone, buprenorphine 
depot, and naloxone; and from Reckitt Benckiser for the development of 
an opioid-related behaviour scale, and a study of opioid substitution 
therapy uptake among patients with chronic non-cancer pain; an untied 
educational grant from Seqirus for studies of tapentadol; and a grant 
from the Australian Therapeutic Goods Administration, all outside the 
submitted work. GCh, FB, MS, and TD declare no competing interests.
Acknowledgments
GCa, BL, AP, SN, and LD are supported by National Health and Medical 
Research Council fellowships (grant numbers 1119992, 1073858, 1109366, 
1132433, 1041472, and 1135991). This study was funded by the Australian 
Government and the National Health and Medical Research Council. 
The Australian National Drug and Alcohol Research Centre, University 
of New South Wales Sydney, is supported by funding from the 
Australian Government, under the Substance Misuse Prevention and 
Service Improvements Grant Fund. We thank our associate investigators, 
members of the POINT advisory committee, and the POINT research 
team. We thank the members of our POINT cohort, whose willingness 
to share their experiences was essential.
References
1 Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of 
long-term opioid therapy for chronic pain: a systematic review for a 
National Institutes of Health Pathways to Prevention Workshop. 
Ann Intern Med 2015; 162: 276–86.
2 Krebs EE, Gravely A, Nugent S, et al. Effect of opioid vs nonopioid 
medications on pain-related function in patients with chronic back 
pain or hip or knee osteoarthritis pain: the space randomized 
clinical trial. JAMA 2018; 319: 872–82.
3 Fischer B, Argento E. Prescription opioid related misuse, harms, 
diversion and interventions in Canada: a review. Pain Physician 
2012; 15 (3 suppl): ES191–203.
4 Fischer B, Rehm J. Revisiting the ‘paradigm shift’ in opioid use: 
developments and implications 10 years later. Drug Alcohol Rev 2017; 
37: S199–202.
5 Nugent SM, Morasco BJ, O’Neil ME, et al. The effects of cannabis 
among adults with chronic pain and an overview of general harms: 
a systematic review. Ann Intern Med 2017; 167: 319–31.
6 Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for 
medical use: a systematic review and meta-analysis. JAMA 2015; 
313: 2456–73.
7 Stockings E, Campbell G, Hall W, et al. Cannabis and cannabinoids 
for the treatment of people with chronic non-cancer pain 
conditions: a systematic review and meta-analysis of controlled and 
observational studies. Pain 2018; published online May 25. 
DOI:10.1097/j.pain.0000000000001293.
8 National Academies of Sciences, Engineering, and Medicine. 
The health effects of cannabis and cannabinoids: the current state 
of evidence and recommendations for research. Washington, DC: 
The National Academies Press, 2017.
9 Walsh Z, Callaway R, Belle-Isle L, et al. Cannabis for therapeutic 
purposes: patient characteristics, access, and reasons for use. 
Int J Drug Policy 2013; 24: 511–16.
10 Hazekamp A, Heerdink ER. The prevalence and incidence of 
medicinal cannabis on prescription in the Netherlands. 
Eur J Clin Pharmacol 2013; 69: 1575–80.
11 Nielsen S, Sabioni P, Trigo JM, et al. Opioid-sparing effect of 
cannabinoids: a systematic review and meta-analysis. 
Neuropsychopharmacology 2017; 42: 1752–65.
12 Campbell G, Nielsen S, Bruno R, et al. The Pain and Opioids IN 
Treatment study: characteristics of a cohort using opioids to 
manage chronic non-cancer pain. Pain 2015; 156: 231–42.
13 Australian Government Department of Health Therapeutics 
Goods Administration. Guidance for the use of medicinal 
cannabis in the treatment of chronic non-cancer pain in Australia. 
Version 1, December, 2017. Canberra: Commonwealth of Australia, 
2017.
14 Haroutounian S, Ratz Y, Ginosar Y, et al. The effect of medicinal 
cannabis on pain and quality-of-life outcomes in chronic pain: 
a prospective open-label study. Clin J Pain 2016; 32: 1036–43.
15 Hoggart B, Ratcliffe S, Ehler E, et al. A multicentre, open-label, 
follow-on study to assess the long-term maintenance of effect, 
tolerance and safety of THC/CBD oromucosal spray in the 
management of neuropathic pain. J Neurol 2015; 262: 27–40.
Articles
e350 www.thelancet.com/public-health   Vol 3   July 2018
16 Ware MA, Wang T, Shapiro S, Collet JP. Cannabis for the 
management of pain: assessment of safety study (COMPASS). 
J Pain 2015; 16: 1233–42.
17 Campbell G, Mattick R, Bruno R, et al. Cohort protocol paper: 
the Pain and Opioids In Treatment (POINT) study. 
BMC Pharmacol Toxicol 2014; 15: 17.
18 Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for 
chronic pain clinical trials: IMMPACT recommendations. Pain 
2005; 113: 9–19.
19 Turk DC, Dworkin RH, Allen RR, et al. Core outcome domains for 
chronic pain clinical trials: IMMPACT recommendations. Pain 
2003; 106: 337–45.
20 Cleeland CS. The Brief Pain Inventory (BPI). 1991. https://www.
mdanderson.org/research/departments-labs-institutes/
departments-divisions/symptom-research/symptom-assessment-
tools/brief-pain-inventory.html (accessed June 19, 2018).
21 Nicholas MK. The pain self-efficacy questionnaire: taking pain into 
account. Eur J Pain 2007; 11: 153–63.
22 Nielsen S, Degenhardt L, Hoban B, Gisev N. A synthesis of oral 
morphine equivalents (OME) for opioid utilisation studies. 
Pharmacoepidemiol Drug Saf 2016; 25: 733–37.
23 Kroenke K, Spitzer R, Williams JB. The PHQ-9: validity of a brief 
depression severity measure. J Gen Intern Med 2001; 16: 606–13.
24 Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for 
assessing generalized anxiety disorder: the GAD-7. 
Arch Intern Med 2006; 166: 1092–97.
25 WHO. Composite International Diagnostic Interview, version 3.0. 
Geneva: World Health Organization, 2001.
26 Degenhardt L, Lintzeris N, Campbell G, et al. Experience of adjunctive 
cannabis use for chronic non-cancer pain: findings from the Pain 
and Opioids IN Treatment (POINT) study. Drug Alcohol Depend 2015; 
147: 144–50.
27 Australian Government Australian Institute of Health and Welfare. 
National Drug Strategy Household Survey 2016. Detailed findings. 
Canberra: Australian Institute of Health and Welfare, 2017.
28 Troutt WD, DiDonato MD. Medical cannabis in Arizona: patient 
characteristics, perceptions, and impressions of medical cannabis 
legalization. J Psychoactive Drugs 2015; 47: 259–66.
29 Swift W, Gates P, Dillon P. Survey of Australians using cannabis for 
medical purposes. Harm Reduct J 2005; 2: 18.
30 Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ. Cannabis use 
for chronic non-cancer pain: results of a prospective survey. 
Pain 2003; 102: 211–16.
31 Wilson M, Gogulski HY, Cuttler C, et al. Cannabis use moderates 
the relationship between pain and negative affect in adults with 
opioid use disorder. Addict Behav 2018; 77: 225–31.
32 Corroon JM Jr, Mischley LK, Sexton M. Cannabis as a substitute for 
prescription drugs—a cross-sectional study. J Pain Res 2017; 
10: 989–98.
33 Reiman A, Welty M, Solomon P. Cannabis as a substitute for 
opioid-based pain medication: patient self-report. 
Cannabis Cannabinoid Res 2017; 2: 160–66.
34 Darke S. Self-report among injecting drug users: a review. 
Drug Alcohol Depend 1998; 51: 10.
35 Lance CE, Vandenberg RJ. Statistical and methodological myths 
and urban legends: doctrine, verity and fable in the organizational 
and social sciences. New York: Taylor & Francis Group, 2009.
36 Abuhasira R, Schleider LB, Mechoulam R, Novack V. 
Epidemiological characteristics, safety and efficacy of medical 
cannabis in the elderly. Eur J Intern Med 2018; 49: 44–50.
37 Boehnke KF, Litinas E, Clauw DJ. Medical cannabis use is 
associated with decreased opiate medication use in a retrospective 
cross-sectional survey of patients with chronic pain. J Pain 2016; 
17: 739–44.
38 Norberg MM, Mackenzie J, Copeland J. Quantifying cannabis use 
with the timeline followback approach: a psychometric evaluation. 
Drug Alcohol Depend 2012; 121: 247–52.
39 van der Pol P, Liebregts N, de Graaf R, Korf DJ, van den Brink W, 
van Laar M. Validation of self-reported cannabis dose and potency: 
an ecological study. Addiction 2013; 108: 1801–18.
